

Table 1. Patient characteristics.

Variables	Total (n = 94)	Control (n = 59)	AZA-VEN (n = 35)	P
Demographic Characteristics				
Age at transplantation, years, median (Range)	47 (18, 70)	49 (18, 70)	46 (25, 66)	0.366
Recipient gender, n (%)				0.135
Male	47 (50.00)	26 (44.07)	21 (60.00)	
Female	47 (50.00)	33 (55.93)	14 (40.00)	
ECOG, n (%)				0.980
0	67 (71.28)	42 (71.19)	25 (71.43)	
1	27 (28.72)	17 (28.81)	10 (28.57)	
Disease Characteristics				
Diagnosis, n (%)				1.000
AML	82 (87.23)	51 (86.44)	31 (88.57)	
Favorable/Intermediate	41 (50.00)	27 (52.94)	14 (45.16)	0.494
Adverse	41 (50.00)	24 (47.06)	17 (54.84)	
MDS	12 (12.77)	8 (13.56)	4 (11.43)	
Pre-transplant venetoclax exposure, n (%)				0.747
No	45 (47.87)	29 (49.15)	16 (45.71)	
Yes	49 (52.13)	30 (50.85)	19 (54.29)	
Disease status at transplantation, n (%)				0.476
Non-CR	23 (24.47)	13 (22.03)	10 (28.57)	
CR	71 (75.53)	46 (77.97)	25 (71.43)	
Pre-transplant MRD status, n (%)				0.700
Negative	40 (42.55)	26 (44.07)	14 (40.00)	
Positive	54 (57.45)	33 (55.93)	21 (60.00)	
Transplantation Characteristics				
Donor type, n (%)				1.000
Haploidentical	85 (90.43)	53 (89.83)	32 (91.43)	
MRD/MUD	9 (9.57)	6 (10.17)	3 (8.57)	
Donor gender, n (%)				0.989
Male	59 (62.77)	37 (62.71)	22 (62.86)	
Female	35 (37.23)	22 (37.29)	13 (37.14)	
ABO match, n (%)				0.909
Mismatched	41 (43.62)	26 (44.07)	15 (42.86)	
Matched	53 (56.38)	33 (55.93)	20 (57.14)	
TBI-based conditioning, n (%)				0.402
No	64 (68.09)	42 (71.19)	22 (62.86)	
Yes	30 (31.91)	17 (28.81)	13 (37.14)	
Conditioning Regimen, n (%)				0.135

RIC	36 (38.30)	26 (44.07)	10 (28.57)	
MAC	58 (61.70)	33 (55.93)	25 (71.43)	
Graft				
Nucleated cell counts, ×10⁹/kg, median (Range)	14.90 (12.03, 19.01)	16.51 (6.78, 43.37)	14.52 (8.23, 34.45)	0.472
CD34+ cell counts, ×10⁶/kg, median (Range)	10.66 (8.22, 13.32)	10.13 (2.62, 27.17)	11.05 (3.22, 18.41)	0.801
CD3+ cell counts, ×10⁹/kg, median (Range)	2.98 (2.30, 3.71)	2.96 (1.29, 8.55)	2.99 (1.43, 6.6)	0.795

Note: Data are presented as n (%) or median (range).

Abbreviations: AZA-VEN, azacitidine plus venetoclax; ECOG, Eastern Cooperative Oncology Group performance status; AML, acute myeloid leukemia; MDS, myelodysplastic syndromes; CR, complete remission; MRD, measurable residual disease; MRD, matched related donor; MUD, matched unrelated donor; TBI, total body irradiation; RIC, reduced-intensity conditioning; MAC, myeloablative conditioning.